comparemela.com

Latest Breaking News On - Pharma analyst - Page 3 : comparemela.com

GlobalData : Early diagnosis continues to pose challenges for Parkinson s disease-modifying therapies, says GlobalData -March 11, 2024 at 10:19 am EDT

11 Mar, 2024 Early diagnosis continues to pose challenges for Parkinson s disease-modifying therapies, says GlobalData Share .

Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies, says GlobalData

Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies, says GlobalData
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies, says GlobalData

Takeda oncology pipeline remains robust despite shift in focus from CAR-T to allogeneic cell therapies, says GlobalData

Otsuka s new formulations to offset Abilify Maintena dual patent expiry impact, says GlobalData - Pharma News

Otsuka s new formulations to offset Abilify Maintena dual patent expiry impact, says GlobalData - Pharma News
financialexpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialexpress.com Daily Mail and Mail on Sunday newspapers.

Otsuka s new formulations to offset Abilify Maintena dual patent expiry impact, says GlobalData

Otsuka Pharmaceutical is poised for a strategic transition as it approaches the loss of market exclusivity of Abilify Maintena (Aripiprazole) in Europe and the US in October 2024. This significant development signals a forthcoming shift in the drug’s sales trajectory, highlighting Otsuka’s readiness to embrace .

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.